Treatment of BCL-1 Murine B-Cell Leukemia with Recombinant Cytokines: Comparative Analysis of the Anti-Leukemic Potential of Interleukin 1 Beta (IL-1 β), Interleukin 2 (IL-2), Interleukin-6 (IL-6), Tumor Necrosis Factor Alpha (TNFα), Granulocyte Colony Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), and their Combination

References

• Chaplin R., Gale R. P. Acute lymphoblastic leukemia: Recent advances in biology and therapy. Blood 1989; 73: 2051–2066
   PubMed Web of Science ®Google Scholar
• Rivera G. K., Buchanan G., Boyett J. M., Camitta B., Ochs J., Kalwinsky D., Amvlon M., Vietti T. J., Crist W. J. Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse: A pediatric oncology groups study. N. Engl. J. Med 1986; 315: 273–278
   PubMed Web of Science ®Google Scholar
• Treatment of childhood acute lymphoblastic leukemia. Lancet 1988; 1: 683–685, (editorial)
   PubMed Web of Science ®Google Scholar
• Barrett J., Horowitz M. M., Gale R. P., Biggs J. C., Camitta B. M., Dicke K. A., Gluckman E., Good R. A., Herzig R. H., Lee M. B., Marmont A. M., Masoaka T., Ramsay N. K. C., Rimm A. A., Speck B., Zwaan F. E., Bortin M. M. Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival. Blood 1989; 74: 862–871
   PubMed Web of Science ®Google Scholar
• Kersey J. H., Weisdorf D., Nesbit M. E., Le Bien T. W., Woods W. G., McGlave P. B., Kim T., Vallera D. A., Goldman A. I., Bostrom B., Hurd D., Ramsay N. K. C. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N. Engl. J. Med. 1987; 317: 461–467
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Kersey J. H., Vallera D. A., Ledbetter J. A., Weisdorf D., Myers D. E., Haake R., Ramsay N. K. C. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723–1733
   PubMed Web of Science ®Google Scholar
• Herzig R. H., Barrett A. J., Gluckman E., Jacobsen S. J., Masoaka T., Ramsay N. K. C., Ringden O., Zwaan F. E., Bortin M. M., Blume K. G., Horowitz M. M., Marmont A., Prentice R. G., Rimm A. A., Speck B., Gale R. P. Bone-marrow transplantation in high-risk acute lymphoblastic leukemia in first and second remission. Lancet 1987; 1: 786–789
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Kersey J. H., Waddick K. G., Haake R., Weisdorf D., Ledbetter J. A., Ramsay N. K. C. Autologous bone marrow transplantation (BMT) in high risk remission B-lineage acute lymphoblastic leukemia (ALL) using a cocktail of three monoclonal antibodies (BA-I/CD24, BA-2/CD9, BA-3/CD10) plus complement (C) and 4-hydro-peroxy-cyclophosphamide (4-HC) for ex vivo bone marrow purging. Blood 1991, in press
   Web of Science ®Google Scholar
• Uckun F. M., Haake R., Kersey J. H., Haissig S., Weisdorf D., C-Langlie M., Nesbit M., Ramsay N. K. C. Impact of the pre-transplant residual leukemia border of high risk acute lymphoblastic leukemia patients on the probability of relapse after analogous bone marrow transplantation. Blood 1991; 78(No. 10, Suppl.l), Abstr. No 757
   Google Scholar
• Fabian I., Kletter Y., Slavin S. Therapeutic potential of recombinant granulocyte-macrophage colony-stimulating factor and interleukin-3 in murine B-cell leukemia. Blood 1988; 72: 913–918
   PubMed Web of Science ®Google Scholar
• Slavin S., Ackerstein A., Kedar E., Weiss L. IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2. Bone Marrow Transplant 1990; 6(Suppl.1)86–90
   PubMedGoogle Scholar
• Cameron McIntosh R. B.J. K., Rosenberg S. A. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Research 1988; 48: 5810–5817
   PubMed Web of Science ®Google Scholar
• Borberg H., Abdallah A., Schwulera U, Sonneborn H. Inhibition of tumor growth in a mouse fibrosarcoma after interleukin 2 application. Immunohiology 1986; 172: 383–390
   PubMed Web of Science ®Google Scholar
• Mazumder A., Rosenberg S. A. Succesful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. Journal of Experimental Medicine 1984; 159: 495–507
   PubMed Web of Science ®Google Scholar
• Vaage J. Local and systemic effects during interleukin-2 therapy of mouse mammary tumors. Cancer Research 1987; 47: 4296–4298
   PubMed Web of Science ®Google Scholar
• Kataoka T., Matsuura N., Oh-Hashi G., Suhara Y. Treatment regimen and host T-cell-dependent therapeutic effect of interferon in mouse solid tumors. Cancer Research 1985; 45: 3548–3553
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Skibber Y. L.J. M., Shiloni E., Vetto J. T., Seipp C. A., Simpson C., Reichert C. M. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin to patients with metastatic cancer. New England Journal of Medicine 1985; 313: 1485–1492
   PubMed Web of Science ®Google Scholar
• Young M. R., Young M. E., Wepsic H. T. The effect of recombinant murine interferon-gamma on the hematopoietic and immunological parameters of mice bearing metastatic Lewis lung carcinoma tumors. Experimental Hematology 1988; 16: 295–301
   PubMed Web of Science ®Google Scholar
• Cheever M. A., Greenberg P. D., Fefer A., Gillis S. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin. Journal of Experimental Medicine 1982; 155: 968–980
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Mule J. J., Spiess P. J., Reichert C. M., Schwarz S. L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. Journal of Experimental Medicine 1985; 161: 1169–1188
   PubMed Web of Science ®Google Scholar
• Grimm E. A., Mazumdar A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Journal of Experimental Medicine 1982; 155: 1823–1841
   PubMed Web of Science ®Google Scholar
• Fabian I., Kletter Y., Slavin S. Therapeutic potential of recombinant granulocyte-macrophage colony-stimulating factor and interleukin-2 in murine B-cell leukemia. Blood 1988; 72: 913–918
   PubMed Web of Science ®Google Scholar
• Hefeneider S. A., Conlon P. J., Henney C. S., Gillis S. In vivo interleukin-2 administration augments the generation of alloreactive cytolytic T lymphocyte and resident natural killer cells. The Journal of Immunology 1983; 130: 222–227
   PubMed Web of Science ®Google Scholar
• Luger T. A., Krutman J., Kirnbauer R., Urbanski A., Schwarz T., Klappacher G., Kock A., Micksche M., Malejczyk J., Schauer E., May L. T., Sehgal P. B. IFN-β2/IL-6 augments the activity of human natural killer cells. The Journal of Immunology 1989; 143: 1206–1209
   PubMed Web of Science ®Google Scholar
• Talmage J. E., Tribble H., Pennington R., Bowersox O., Scneider M. A., Castelli P., Black P. L., Abe F. Protective, restorative, and therapeutic properties of recombinant colony-stimulating factors. Blood 1989; 73: 2093–2103
   PubMed Web of Science ®Google Scholar
• Maas R., Dullens H. F. J., De Jong W. H., Den Otter W. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Research 1989; 49: 7037–7040
   PubMed Web of Science ®Google Scholar
• McIntosh J. K., Mule J. J., Merino M. J., Rosenberg S. A. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha. Cancer Research 1988; 48: 4011–4017
   PubMed Web of Science ®Google Scholar
• Talmadge J. E., Tribble H. R., Pennington R. W., Phillips H., Wiltrout R. H. Immunomodulatory and immu-notherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. Cancer Research 1987; 47: 2563–2570
   PubMed Web of Science ®Google Scholar
• Vuist W. M. J., Buitenen F., de Rie M. A. V., Hekman A., Riimke P., Melief C. J. M. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti CD19) monoclonal antibodies in a mouse xenotransplantation model. Cancer Research 1989; 49: 3783–3788
   PubMed Web of Science ®Google Scholar
• Tepper R. I., Pattengale P. K., Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503–512
   PubMed Web of Science ®Google Scholar
• Agah R., Malloy B., Sherrod A., Mazumder A. Successful therapy of natural killer-resistant pulmonary metastases by the synergism of gamma-interferon with tumor-necrosis factor and interleukin-2 in mice. Cancer Research 1988; 48: 2245–2248
   PubMed Web of Science ®Google Scholar
• Vaage J. Local interleukin 2 therapy of mouse mammary tumors of various immunogenicities. Cancer Research 1988; 48: 2193–2197
   PubMed Web of Science ®Google Scholar
• Marquet R. L., Ijzermans J. N. M., De Bruin R. W. F., Fiers W., Jeekel J. Anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) on colon in rats is promoted by recombinant rat interferon gamma; toxicity is reduced by indomethacin. International Journal of Cancer 1987; 40: 550–553
   PubMed Web of Science ®Google Scholar
• Brunda M. J., Ballantoni D., Sulich V. In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. International Journal of Cancer 1987; 40: 365–371
   PubMed Web of Science ®Google Scholar
• Silagi S., Dutkowski R., Schaefer A. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferin-gamma. International Journal of Cancer 1988; 41: 315–322
   PubMed Web of Science ®Google Scholar
• Nishiyama Y., Fuchimoto S., Orita K. Preventive and antiproliferative effects of tumor necrosis factor against experimental hepatic metastases of mouse colon-26 tumor. Jpn. J. Cancer. Res. 1989; 80: 366–372
   PubMedGoogle Scholar
• Talpaz M., Kantarjian H., Kurzrock R., Trujillo J. M., Gutterman J. U. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Annals of Internal Medicine 1991; 114: 532–538
   PubMed Web of Science ®Google Scholar
• Gillis S., Conlon P. J., Cosman D., Hopp Dower T. P., Price S. K., Mochizuki D. Y.V., Urdal D. L. Lymphokines: from conjecture to the clinic. Seminars in Oncology 1986; 13: 218–227
   PubMed Web of Science ®Google Scholar
• Mule J. J., Schu S., Schwarz S. L., Rosenberg S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487–1489
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Adoptive immunotherapy for cancer. Scientific American 1990; 5: 62–69
   Google Scholar
• Slavin S., Strober S. Spontaneous murine B cell leukemia. Nature 1977; 272: 624–626
   Web of Science ®Google Scholar
• Krolick K. A., Isakson P. C., Uhr J. W., Vitetta E. S. Murine B cell leukemia (BCL1): organ distribution and kinetics of growth as determined by fluorescence analysis with an anti-idiotypic antibody. J Immunol. 1979; 123: 1928–1935
   PubMed Web of Science ®Google Scholar
• Fulton R. J., Tucker T. F., Vitetta E. S., Uhr J. W. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization. Cancer Res. 1988; 48: 2618–2625
   PubMed Web of Science ®Google Scholar
• Fulton R. J., Uhr J. W., Vitetta E. S. In vivo therapy of the BCL, tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain. Cancer Res. 1988; 48: 2626–2631
   PubMed Web of Science ®Google Scholar
• George A. J. T., Spellerberg M. F., Stevenson F. K. Idiotype vaccination leads to the emergence of a stable surface Ig-negative variant of the mouse lymphoma BCL, with different growth characteristics. J. Immunol. 1988; 140: 1695–1701
   PubMed Web of Science ®Google Scholar
• Schreiber K. L., Forman J. Effect of graft-versus-host disease on anti-tumor immunity. J. Immunol. 1990; 144: 2018–2026
   PubMed Web of Science ®Google Scholar
• Shima J., Yoshioka T., Nakajima H., Fujiwara H., Hamaoka T. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity. Cancer Immunol. Immunother. 1988; 26: 43–47
   PubMed Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics rising in its consideration. Cancer Chemother. Rep. 1966; 50: 163–170
   PubMedGoogle Scholar
• Matthews D. W., Farewell V. T. The log-rank or Mantel-Haenszel test for the comparison of survival curves. Using and Understanding Medical Statistics, D. E. Matthews, V. T. Farewell. Karger, BaselSwitzerland 1988; 79
   Google Scholar
• Waddick K. G., Song C. W., Souza L., Uckun F. M. Comparative analysis of the in vivo radioprotective effect of recombinant G-CSF, recombinant GM-CSF and their combination. Blood 1991; 11: 2364
   Google Scholar
• Uckun F. M., Song C. W., Wick W., Waddick K. G., Souza L. In vivo radioprotective effects of recombinant human granulocyte colony stimulating factor in lethally irradiated mice. Blood 1990; 75: 638–645
   PubMed Web of Science ®Google Scholar